(Q41046077)

26 September 2017

1 reference

title

Nonlipid primary and secondary prevention strategies for coronary heart disease (English)

1 reference

26 September 2017

Maron DJ

1

1 reference

26 September 2017

publication date

1 May 1996

1 reference

26 September 2017

1 reference

26 September 2017

volume

19

1 reference

26 September 2017

issue

5

1 reference

26 September 2017

page(s)

419-423

1 reference

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

Statement on smoking and cardiovascular disease for health care professionals. American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

7 January 2021

Mortality in relation to smoking: 20 years' observations on male British doctors

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

7 January 2021

Relative and Absolute Excess Risks of Coronary Heart Disease among Women Who Smoke Cigarettes

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

7 January 2021

The primary prevention of myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

7 January 2021

Cost-effectiveness analysis in heart disease, Part II: Preventive therapies

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

7 January 2021

Blood pressure, stroke, and coronary heart disease

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

7 January 2021

Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

7 January 2021

Statement on exercise. Benefits and recommendations for physical activity programs for all Americans. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

7 January 2021

Body weight and mortality

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

7 January 2021

An Overview of the British and American Aspirin Studies

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

7 January 2021

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

7 January 2021

Estrogen and coronary heart disease in women

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

7 January 2021

The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

7 January 2021

Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

7 January 2021

Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

7 January 2021

Regional Variation across the United States in the Management of Acute Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

7 January 2021

Proischemic complications of dihydropyridine calcium channel blockers

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

7 January 2021

Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

7 January 2021

The effect of diltiazem on mortality and reinfarction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190517

7 January 2021

Identifiers

DOI

10.1002/CLC.4960190517

1 reference

26 September 2017

1 reference